Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature

Enrolling by invitation

Conditions studied: Coronary Microvascular Dysfunction, Cardiotoxicity, Breast Cancer, Lung Cancer (NSCLC)

In brief

This is an observational study that includes patients with breast cancer or non-small cell lung cancer who will be treated with immune checkpoint inhibitor (ICI) therapy. The investigators will use echocardiograms, blood draws, and PET stress tests to understand how ICI therapy affects the heart and circulatory system.

Key facts

Study ID

NCT06332131

Run by

Abramson Cancer Center at Penn Medicine

People needed

25

Starts

2025-01-15

Expected to finish

2026-07-01

Last updated by the study team

2026-02-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• ≥18 years of age
• Either diagnosis of breast cancer with plan for treatment according to the Keynote 522 regimen or non-small-cell lung cancer planned for neoadjuvant treatment that includes pembrolizumab
• Able to provide written informed consent

You may not qualify if…

• Pregnant or breast-feeding:
• Prior treatment with ICI therapy.
• Vulnerable patients, including pregnant women and prisoners
• Absolute Contraindication to rest/vasodilator stress PET/CT

Where it is running

• Abramson Cancer Center at University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.